Linked Life Data

14566838

Source:http://linkedlifedata.com/resource/pubmed/id/14566838

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2003-10-20
pubmed:abstractText
The FHIT tumor suppressor gene, which encompasses the fragile site FRA3B at 3p14.2, is altered frequently in many types of human cancers. To determine its importance as a prognostic marker in breast cancer, the expression of the FHIT protein was studied in a series of 452 breast carcinomas by using immunohistochemistry on sections of tissue microarrays. Three distinct levels of FHIT expression were observed: in 154 cases (34.1%) expression was unchanged as compared to normal level; in 78 (17.2%) no expression was found; in the remaining 220 cases (48.7%), expression was intermediate. Overall, two-thirds of the cases had abnormal levels of the protein. Absence of FHIT was significantly associated with a higher grade (p < 0.01) and absence of hormone receptors (p < 0.001). The patients were separated into Group I (153 node-negative good prognosis patients who did not receive adjuvant chemotherapy) and Group II (226 high-risk patients treated by adjuvant chemotherapy) according to the St.-Gallen conference consensus. The median follow-up was 48 months. Among Group I but not Group II patients, a multivariate analysis showed that FHIT expression was significantly associated with disease-free survival. The relative risk of recurrence for FHIT-negative Group I patients was 2.37 (1.21-4.64; p = 0.03). Thus, among the patients who present with tumors of apparent good prognosis, FHIT is an independent prognostic factor that distinguishes a subgroup of patients who could benefit from adjuvant treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0020-7136
pubmed:author
pubmed:copyrightInfo
Copyright 2003 Wiley-Liss, Inc.
pubmed:issnType
Print
pubmed:day
10
pubmed:volume
107
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
854-62
pubmed:dateRevised
2007-7-24
pubmed:meshHeading
pubmed-meshheading:14566838-Acid Anhydride Hydrolases, pubmed-meshheading:14566838-Adult, pubmed-meshheading:14566838-Breast Neoplasms, pubmed-meshheading:14566838-Female, pubmed-meshheading:14566838-Gene Deletion, pubmed-meshheading:14566838-Genes, Tumor Suppressor, pubmed-meshheading:14566838-Humans, pubmed-meshheading:14566838-Lymphatic Metastasis, pubmed-meshheading:14566838-Middle Aged, pubmed-meshheading:14566838-Neoplasm Invasiveness, pubmed-meshheading:14566838-Neoplasm Proteins, pubmed-meshheading:14566838-Oligonucleotide Array Sequence Analysis, pubmed-meshheading:14566838-Prognosis, pubmed-meshheading:14566838-Reproducibility of Results, pubmed-meshheading:14566838-Survival Analysis, pubmed-meshheading:14566838-Time Factors, pubmed-meshheading:14566838-Tumor Markers, Biological
pubmed:year
2003
pubmed:articleTitle
Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer.
pubmed:affiliation
Département d'Oncologie Moléculaire, Institut Paoli-Calmettes and U119 INSERM, IFR57, Marseille, France.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't